In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: Involvement of soluble HLA-I and Fas ligand

P. Contini, M. R. Zocchi, I. Pierri, A. Albarello, A. Poggi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In this study, we show that high serum levels of soluble human leukocyte antigens (HLA) class I molecules (sHLA-I, range: 0.7-1.7μg/ml) and soluble Fas ligand (FasL, range: 0.4-1.9ng/ml) are detected in patients with acute myeloid leukemia (AML) at diagnosis, compared with healthy donors (HD) (sHLA-I, range: 0.1-0.6μg/ml; sFasL, range: 0.1-0.4ng/ ml). Patients' sera were able to induce transcription and secretion of FasL in CD8+ T cells, followed by apoptosis in vitro; this apoptosis was inhibited by anti-HLA-I-specific monoclonal antibodies, suggesting that sHLA-I is responsible for cell death. These findings closely relate to the in vivo upregulation of FasL transcription observed in peripheral blood (PB) lymphocytes from AML patients; in the same cells, mRNA for the antiapoptotic proteins Bcl-2 and Bcl-xL was downregulated. Interestingly, caspase-8 and caspase-3, both downstream mediators of death receptor-induced apoptosis, were activated in CD8+ cells of AML patients; one-third of these cells were already apoptotic in vivo, at variance with lymphocytes of HD. These data strongly suggest that in AML, increased levels of sHLA-I molecules may contribute to the elimination of potentially anti-tumor effector cells through a FasL/Fas interaction.

Original languageEnglish
Pages (from-to)253-260
Number of pages8
JournalLeukemia
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Patient Participation
Fas Ligand Protein
HLA Antigens
Acute Myeloid Leukemia
Lymphocytes
Apoptosis
Tissue Donors
Death Domain Receptors
Caspase 8
Serum
Caspase 3
Cell Death
Up-Regulation
Down-Regulation
Monoclonal Antibodies
T-Lymphocytes
Messenger RNA
Neoplasms
Proteins

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients : Involvement of soluble HLA-I and Fas ligand. / Contini, P.; Zocchi, M. R.; Pierri, I.; Albarello, A.; Poggi, A.

In: Leukemia, Vol. 21, No. 2, 02.2007, p. 253-260.

Research output: Contribution to journalArticle

@article{2a98fdb741cb489b8eefc82eb4324327,
title = "In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: Involvement of soluble HLA-I and Fas ligand",
abstract = "In this study, we show that high serum levels of soluble human leukocyte antigens (HLA) class I molecules (sHLA-I, range: 0.7-1.7μg/ml) and soluble Fas ligand (FasL, range: 0.4-1.9ng/ml) are detected in patients with acute myeloid leukemia (AML) at diagnosis, compared with healthy donors (HD) (sHLA-I, range: 0.1-0.6μg/ml; sFasL, range: 0.1-0.4ng/ ml). Patients' sera were able to induce transcription and secretion of FasL in CD8+ T cells, followed by apoptosis in vitro; this apoptosis was inhibited by anti-HLA-I-specific monoclonal antibodies, suggesting that sHLA-I is responsible for cell death. These findings closely relate to the in vivo upregulation of FasL transcription observed in peripheral blood (PB) lymphocytes from AML patients; in the same cells, mRNA for the antiapoptotic proteins Bcl-2 and Bcl-xL was downregulated. Interestingly, caspase-8 and caspase-3, both downstream mediators of death receptor-induced apoptosis, were activated in CD8+ cells of AML patients; one-third of these cells were already apoptotic in vivo, at variance with lymphocytes of HD. These data strongly suggest that in AML, increased levels of sHLA-I molecules may contribute to the elimination of potentially anti-tumor effector cells through a FasL/Fas interaction.",
author = "P. Contini and Zocchi, {M. R.} and I. Pierri and A. Albarello and A. Poggi",
year = "2007",
month = "2",
doi = "10.1038/sj.leu.2404494",
language = "English",
volume = "21",
pages = "253--260",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients

T2 - Involvement of soluble HLA-I and Fas ligand

AU - Contini, P.

AU - Zocchi, M. R.

AU - Pierri, I.

AU - Albarello, A.

AU - Poggi, A.

PY - 2007/2

Y1 - 2007/2

N2 - In this study, we show that high serum levels of soluble human leukocyte antigens (HLA) class I molecules (sHLA-I, range: 0.7-1.7μg/ml) and soluble Fas ligand (FasL, range: 0.4-1.9ng/ml) are detected in patients with acute myeloid leukemia (AML) at diagnosis, compared with healthy donors (HD) (sHLA-I, range: 0.1-0.6μg/ml; sFasL, range: 0.1-0.4ng/ ml). Patients' sera were able to induce transcription and secretion of FasL in CD8+ T cells, followed by apoptosis in vitro; this apoptosis was inhibited by anti-HLA-I-specific monoclonal antibodies, suggesting that sHLA-I is responsible for cell death. These findings closely relate to the in vivo upregulation of FasL transcription observed in peripheral blood (PB) lymphocytes from AML patients; in the same cells, mRNA for the antiapoptotic proteins Bcl-2 and Bcl-xL was downregulated. Interestingly, caspase-8 and caspase-3, both downstream mediators of death receptor-induced apoptosis, were activated in CD8+ cells of AML patients; one-third of these cells were already apoptotic in vivo, at variance with lymphocytes of HD. These data strongly suggest that in AML, increased levels of sHLA-I molecules may contribute to the elimination of potentially anti-tumor effector cells through a FasL/Fas interaction.

AB - In this study, we show that high serum levels of soluble human leukocyte antigens (HLA) class I molecules (sHLA-I, range: 0.7-1.7μg/ml) and soluble Fas ligand (FasL, range: 0.4-1.9ng/ml) are detected in patients with acute myeloid leukemia (AML) at diagnosis, compared with healthy donors (HD) (sHLA-I, range: 0.1-0.6μg/ml; sFasL, range: 0.1-0.4ng/ ml). Patients' sera were able to induce transcription and secretion of FasL in CD8+ T cells, followed by apoptosis in vitro; this apoptosis was inhibited by anti-HLA-I-specific monoclonal antibodies, suggesting that sHLA-I is responsible for cell death. These findings closely relate to the in vivo upregulation of FasL transcription observed in peripheral blood (PB) lymphocytes from AML patients; in the same cells, mRNA for the antiapoptotic proteins Bcl-2 and Bcl-xL was downregulated. Interestingly, caspase-8 and caspase-3, both downstream mediators of death receptor-induced apoptosis, were activated in CD8+ cells of AML patients; one-third of these cells were already apoptotic in vivo, at variance with lymphocytes of HD. These data strongly suggest that in AML, increased levels of sHLA-I molecules may contribute to the elimination of potentially anti-tumor effector cells through a FasL/Fas interaction.

UR - http://www.scopus.com/inward/record.url?scp=33846534192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846534192&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404494

DO - 10.1038/sj.leu.2404494

M3 - Article

C2 - 17170722

AN - SCOPUS:33846534192

VL - 21

SP - 253

EP - 260

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -